Exelon Dementia Indication May Revive Flagging Sales, Novartis Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Novartis' Alzheimer's disease therapy Exelon (rivastigmine tartrate) have taken a hit in the U.S. due to increased competition, the company said
You may also be interested in...
Exelon Panel To Debate Parkinson’s-Related Dementia As Distinct Condition
Novartis’ sNDA for the Alzheimer’s therapy is the first application for a Parkinson’s-related dementia indication.
Exelon Panel To Debate Parkinson’s-Related Dementia As Distinct Condition
Novartis’ sNDA for the Alzheimer’s therapy is the first application for a Parkinson’s-related dementia indication.
Alzheimer’s Therapies “Best Buys” Named By Consumer Reports
Aricept, Razadyne and Namenda are selected for the list despite the poor response associated with Alzheimer’s.